
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics is positioned favorably in the life sciences sector due to the meaningful increase in Chromium reaction volumes, indicating a robust market despite ongoing pricing pressures. The company's consumables have outpaced instrument revenue growth, with projections suggesting a remarkable 5-19x growth in consumables per platform by 2027. This trend underscores the strong demand for 10x Genomics’s integrated solutions, enhancing the company’s long-term financial outlook.
Bears say
10x Genomics has experienced a contraction in 2024, marked by double-digit pricing pressures and flat to modestly lower volume growth, with no anticipated recovery until 2027. The company's recent earnings report revealed a significant miss in Q4 results, posting an EPS of -$0.40 compared to expectations of -$0.30, alongside a disappointing full-year revenue outlook. Furthermore, despite sector expansion since its peak in 2021, the company's stock has declined over 90%, reflecting a performance below analyst expectations.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares